AEON Biopharma Past Earnings Performance
Past criteria checks 0/6
AEON Biopharma's earnings have been declining at an average annual rate of -69.2%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 162% per year.
Key information
-69.2%
Earnings growth rate
-61.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -162.0% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How AEON Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -306 | 19 | 25 |
| 31 Mar 24 | 0 | -137 | 21 | 30 |
| 31 Dec 23 | 0 | -385 | 20 | 33 |
| 30 Sep 23 | 0 | -45 | 21 | 36 |
| 30 Jun 23 | 0 | -78 | 17 | 35 |
| 31 Mar 23 | 0 | -66 | 15 | 35 |
| 31 Dec 22 | 0 | -53 | 14 | 35 |
| 30 Sep 22 | 0 | -25 | 12 | 33 |
| 30 Jun 22 | 0 | -27 | 12 | 33 |
| 31 Mar 22 | 0 | -61 | 11 | 29 |
| 31 Dec 21 | 0 | -56 | 11 | 26 |
| 30 Sep 21 | 1 | -58 | 10 | 21 |
| 30 Jun 21 | 1 | -54 | 11 | 16 |
| 31 Mar 21 | 2 | -17 | 11 | 12 |
| 31 Dec 20 | 3 | -50 | 12 | 7 |
| 31 Dec 19 | 3 | 137 | 46 | 5 |
| 31 Dec 18 | 2 | -101 | 32 | 14 |
Quality Earnings: AEON is currently unprofitable.
Growing Profit Margin: AEON is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AEON is unprofitable, and losses have increased over the past 5 years at a rate of 69.2% per year.
Accelerating Growth: Unable to compare AEON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AEON is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: AEON's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.